SEC Form 4 · accession 0001225208-18-015222
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian C Read
Officer — Chairman & CEO · Director
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 3:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 2, 2018 | M | 458,506 | $21.03 | A | 1,119,263 | D | |
| Common StockF1 | Nov 2, 2018 | M | 280,503 | $27.37 | A | 1,399,766 | D | |
| Common StockF2 | Nov 2, 2018 | M | 212,200 | $32.23 | A | 1,611,966 | D | |
| Common StockF2 | Nov 2, 2018 | M | 148,992 | $34.59 | A | 1,760,958 | D | |
| Common Stock | holding | — | — | — | 11,265 | I | By Rule 16b-3 Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation Rights | $34.59 | Nov 2, 2018 | M | 483,092 | D | Feb 26, 2018 | Feb 26, 2020 | Common Stock | 483,092 | 0 | D |
| Stock Appreciation Rights | $32.23 | Nov 2, 2018 | M | 548,885 | D | Feb 27, 2017 | Feb 27, 2019 | Common Stock | 548,885 | 0 | D |
| Stock Appreciation Rights | $21.03 | Nov 2, 2018 | M | 668,724 | D | Nov 1, 2016 | Feb 23, 2019 | Common Stock | 668,724 | 0 | D |
| Stock Appreciation Rights | $27.37 | Nov 2, 2018 | M | 539,305 | D | Nov 1, 2016 | Feb 28, 2020 | Common Stock | 539,305 | 0 | D |
Explanation of responses
- F1Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $43.74)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.
- F2Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $43.74)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.